Table 1: Characteristics of patients of malignant germ cell tumors.
|
|
Male (N=38) |
Female(N=37) |
|||
|
Characteristics |
count |
N % |
count |
N % |
|
|
Age group |
1 - 10 years |
4 |
10.5% |
5 |
13.5% |
|
11 - 20 years |
4 |
10.5% |
23 |
62.2% |
|
|
21 - 30 years |
11 |
28.9% |
6 |
16.2% |
|
|
31 - 40 years |
12 |
31.6% |
1 |
2.7% |
|
|
41 - 50 years |
4 |
10.5% |
1 |
2.7% |
|
|
> 50 years |
3 |
7.9% |
1 |
2.7% |
|
|
ECOG PS |
ECOG_0 |
12 |
31.6% |
7 |
18.9% |
|
ECOG_1 |
15 |
39.5% |
13 |
35.1% |
|
|
ECOG_2 |
7 |
18.4% |
13 |
35.1% |
|
|
ECOG_3 |
4 |
10.5% |
4 |
10.8% |
|
|
Presenting complains |
Abdominal pain |
2 |
5.3% |
17 |
45.9% |
|
Abdominal pain and lump |
2 |
5.3% |
15 |
40.5% |
|
|
Bleeding per vagina |
0 |
0.0% |
1 |
2.7% |
|
|
Hemoptysis |
2 |
5.3% |
0 |
0.0% |
|
|
Neck node |
3 |
7.9% |
0 |
0.0% |
|
|
Sacral mass |
2 |
5.3% |
2 |
5.4% |
|
|
Shortness of breath |
0 |
0.0% |
2 |
5.4% |
|
|
Testicular swelling |
27 |
71.1% |
0 |
0.0% |
|
|
Diagnosis |
Dysgerminoma |
0 |
0.0% |
17 |
45.9% |
|
Mediastinal germ cell tumor |
0 |
0.0% |
2 |
5.4% |
|
|
Non dysgerminoma |
0 |
0.0% |
16 |
43.2% |
|
|
Non seminoma |
17 |
44.7% |
0 |
0.0% |
|
|
Seminoma |
19 |
50.0% |
0 |
0.0% |
|
|
Sacrococcygeal teratoma |
2 |
5.3% |
2 |
5.4% |
|
|
Histological subtypes |
Embryonal cell carcinoma |
5 |
13.2% |
3 |
8.1% |
|
Choriocarcinoma |
1 |
2.6% |
0 |
0.0% |
|
|
Immature teratoma |
0 |
0.0% |
5 |
13.5% |
|
|
Mature teratoma |
0 |
0.0% |
0 |
0.0% |
|
|
Mixed GCT |
11 |
28.9% |
3 |
8.1% |
|
|
Endodermal sinus / yolk sac tumor |
2 |
5.3% |
9 |
24.3% |
|
|
Seminoma |
19 |
50.0% |
0 |
0.0% |
|
|
Dysgerminoma |
0 |
0.0% |
17 |
45.9% |
|
|
Metastasis |
No metastasis |
20 |
52.6% |
31 |
83.8% |
|
Ascites |
0 |
0.0% |
4 |
10.8% |
|
|
Inguinal lymph nodes |
2 |
5.3% |
0 |
0.0% |
|
|
Liver |
4 |
10.5% |
1 |
2.7% |
|
|
Lung |
9 |
23.7% |
1 |
2.7% |
|
|
Supraclavicular lymph nodes |
3 |
7.9% |
0 |
0.0% |
|
|
Metastasis at diagnosis |
Yes |
18 |
47.4% |
6 |
16.2% |
|
No |
20 |
52.6% |
31 |
83.8% |
|
|
S- group |
S0 |
0 |
0.0% |
0 |
0.0% |
|
S1 |
17 |
44.7% |
18 |
48.6% |
|
|
S2 |
17 |
44.7% |
16 |
43.2% |
|
|
S3 |
4 |
10.5% |
3 |
8.1% |
|
|
Risk group |
Good |
17 |
44.7% |
18 |
48.6% |
|
Intermediate |
13 |
34.2% |
13 |
35.1% |
|
|
High |
8 |
21.1% |
6 |
16.2% |
|
|
Surgical details |
Biopsy |
6 |
15.8% |
4 |
10.8% |
|
Cytoreductive surgery |
1 |
2.6% |
3 |
8.1% |
|
|
Left high inguinal orchidectomy |
11 |
28.9% |
0 |
0.0% |
|
|
Left salpingo-oophorectomy |
0 |
0.0% |
12 |
32.4% |
|
|
Right high inguinal orchidectomy |
20 |
52.6% |
0 |
0.0% |
|
|
Right salpingo-oophorectomy |
0 |
0.0% |
12 |
32.4% |
|
|
TAH + BSO |
0 |
0.0% |
6 |
16.2% |
|
|
Upfront surgery |
Yes |
32 |
84.2% |
30 |
81.0% |
|
No |
6 |
15.7% |
7 |
18.9% |
|
|
Stage |
Stage I |
5 |
13.2% |
13 |
35.1% |
|
Stage II |
14 |
36.8% |
8 |
21.6% |
|
|
Stage III |
19 |
50.0% |
11 |
29.7% |
|
|
Stage IV |
0 |
0.0% |
5 |
13.5% |
|
|
Treatment defaulted |
Yes |
7 |
18.4% |
5 |
13.5% |
|
No |
31 |
81.6% |
32 |
86.5% |
|
ECOG PS: Eastern Cooperative Oncology Group Performance Scale; S group: serum tumor marker group; GCT: germ cell tumor; TAH and BSO: total abdominal hysterectomy and bilateral salpingo-oophorectomy; BEP: bleomycin, etoposide, cisplatin.